Taylor A. Goodspeed

Taylor Goodspeed's practice largely focuses on pharmaceutical drug pricing, government price reporting, and reimbursement. Taylor has also provided counsel on drug price reporting compliance issues, worked closely with client teams on risk evaluation and mitigation strategies (REMS) compliance, and assisted on limited distribution network (LDN) implementation, including for product launches.

Taylor has significant experience with the 340B Drug Pricing Program (340B Program), having handled day-to-day 340B Program counseling and strategy for a global biopharmaceutical company while on a full-time secondment in 2025. She has held multiple in-house pharmaceutical secondment positions, working within a litigation and government investigation group as well as on a market access and commercial access strategy team. She also has a background in counseling and defending hospitals, health systems, life science companies, and other health care entities in civil fraud and abuse investigations and litigation, particularly under the civil False Claims Act and similar state laws. She has handled numerous litigation and government inquiries affecting the health care industry.

Taylor maintains an active pro bono practice in the anti-trafficking space, serving on Jones Day's Anti-Human Trafficking Committee and previously having served on the American Hospital Association's (AHA) Human Trafficking Advisory Council. Taylor also counsels corporations on mitigating human trafficking-related risks in corporate supply chains and implementing appropriate compliance training and employee policies and procedures on these topics. She has presented on issues of human trafficking in corporate supply chains, including in the health care and real estate industries.